Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKAine dose-escalation pharmacokinetic study after total knee arthroplasty
ACTRN12619000775112Phase 2Completed
- Sponsor
- Foundry Therapeutics
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TKAine and bupivacaine in postoperative pain, sponsored by Foundry Therapeutics. Primary endpoint: Plasma bupivacaine pharmacokinetics. Started Feb 2020; status: completed.
02
Drugs
TKAinebupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ACTRN12619000775112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000775112.